

Flemming SkjÅ,th

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605758/publications.pdf>

Version: 2024-02-01

83
papers

3,963
citations

136885

32
h-index

118793

62
g-index

83
all docs

83
docs citations

83
times ranked

4728
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. <i>Blood Advances</i> , 2022, 6, 2967-2976.	2.5	23
2	Oral anti-øcoagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. <i>British Journal of Haematology</i> , 2022, 197, 223-231.	1.2	6
3	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2022, 63, 285-294.	0.8	10
4	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. <i>Journal of Vascular Surgery</i> , 2022, 75, 1119-1120.	0.6	0
5	Clinical risk factors for retinal artery occlusions: a nationwide case-øcontrol study. <i>International Ophthalmology</i> , 2022, 42, 2483-2491.	0.6	7
6	Assigning diagnosis codes using medication history. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102307.	3.8	6
7	Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. <i>JAMA Network Open</i> , 2022, 5, e2213945.	2.8	10
8	Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting. <i>PharmacoEconomics - Open</i> , 2022, 6, 483-494.	0.9	1
9	Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-11.	1.1	3
10	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. <i>American Journal of Medicine</i> , 2021, 134, 67-75.e5.	0.6	0
11	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark. <i>Circulation</i> , 2021, 143, 907-920.	1.6	12
12	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 31-39.	1.4	5
13	Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2021, 134, 868-876.e5.	0.6	15
14	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. <i>American Journal of Medicine</i> , 2021, , .	0.6	4
15	Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). <i>American Journal of Cardiology</i> , 2020, 125, 48-54.	0.7	20
16	Twenty-øyear time trends in use of evidence-øbased heart failure drug therapy in Denmark. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 30-38.	1.2	3
17	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. <i>Thrombosis Research</i> , 2020, 191, 1-8.	0.8	9
18	Towards Assigning Diagnosis Codes Using Medication History. <i>Lecture Notes in Computer Science</i> , 2020, , 203-213.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Sex differences in risk of incident venous thromboembolism in heart failure patients. <i>Clinical Research in Cardiology</i> , 2019, 108, 101-109.	1.5	15
20	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating “valvular heart disease”™ in a nationwide cohort study. <i>Europace</i> , 2019, 21, 33-40.	0.7	27
21	Non-“Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 939-946.	1.0	34
22	Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. <i>Cancer Medicine</i> , 2019, 8, 1044-1053.	1.3	14
23	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019, 48, 236-243.	0.8	6
24	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 787-794.e4.	0.6	17
25	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. <i>Circulation</i> , 2018, 137, 832-840.	1.6	158
26	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. <i>ESC Heart Failure</i> , 2018, 5, 319-326.	1.4	11
27	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. <i>American Journal of Medicine</i> , 2018, 131, 574.e13-574.e27.	0.6	46
28	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. <i>Scientific Reports</i> , 2018, 8, 15805.	1.6	14
29	Disease progression after ablation for atrial flutter compared with atrial fibrillation: A nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2018, 72, e13258.	0.8	11
30	Causal Inference From Real-World Data. <i>Journal of the American College of Cardiology</i> , 2018, 72, 486-488.	1.2	0
31	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2017, 177, 563.	2.6	75
32	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. <i>Lancet Haematology</i> , 2017, 4, e237-e244.	2.2	36
33	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	187
34	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor. <i>JAMA Cardiology</i> , 2017, 2, 872.	3.0	44
35	Dietary intake and adipose tissue content of long-chain n-3 PUFAs and subsequent 5-y change in body weight and waist circumference. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 1148-1157.	2.2	7
36	Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. <i>BMJ Open</i> , 2017, 7, e018209.	0.8	23

#	ARTICLE	IF	CITATIONS
37	Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	4
38	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j510.	2.4	275
39	The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. <i>PLoS ONE</i> , 2017, 12, e0188482.	1.1	48
40	A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology. <i>Thrombosis and Haemostasis</i> , 2016, 116, 405-406.	1.8	4
41	Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 524-529.	1.8	9
42	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1494-1499.	0.7	11
43	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016, 6, 27410.	1.6	67
44	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ</i> , The, 2016, 353, i3189.	3.0	351
45	β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002597.	1.6	49
46	Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 979-985.	1.0	11
47	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 203, 785-790.	0.8	1
48	Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 403-409.	1.8	15
49	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. <i>Thrombosis and Haemostasis</i> , 2015, 114, 826-834.	1.8	100
50	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. <i>Circulation</i> , 2015, 132, 517-525.	1.6	225
51	Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>Clinical Research in Cardiology</i> , 2015, 104, 1088-1096.	1.5	36
52	Using the CHA2DS2-VASc Score for Stroke Prevention in Atrial Fibrillation: A Focus on Vascular Disease, Women, and Simple Practical Application. <i>Canadian Journal of Cardiology</i> , 2015, 31, 820.e9-820.e10.	0.8	7
53	Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex). <i>Journal of the American College of Cardiology</i> , 2015, 66, 488-490.	1.2	24
54	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2168-2174.	1.0	72

#	ARTICLE	IF	CITATIONS
55	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 147, 1651-1658.	0.4	43
56	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1385-1394.	1.2	141
57	Atrial Fibrillation Patients Categorized as "Not for Anticoagulation" According to the 2014 Canadian Cardiovascular Society Algorithm Are Not "Low Risk". <i>Canadian Journal of Cardiology</i> , 2015, 31, 24-28.	0.8	17
58	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>PLoS ONE</i> , 2014, 9, e114445.	1.1	54
59	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 789-795.	1.8	16
60	Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 1331-1337.	1.0	25
61	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. <i>PLoS ONE</i> , 2014, 9, e113627.	1.1	22
62	Myocardial Ischemic Events in "Real World" Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. <i>American Journal of Medicine</i> , 2014, 127, 329-336.e4.	0.6	63
63	Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 650-656.e5.	0.6	100
64	Does atrial pacing lead to atrial fibrillation in patients with sick sinus syndrome? Insights from the DANPACE trial. <i>Europace</i> , 2014, 16, 241-245.	0.7	16
65	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e21.	0.6	0
66	Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2014, 127, 1172-1178.e5.	0.6	43
67	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 981-988.	1.8	99
68	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. <i>Chest</i> , 2014, 145, 559-566.	0.4	54
69	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. <i>Chest</i> , 2014, 146, 1337-1346.	0.4	34
70	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 946-947.	1.2	4
71	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 61, 596.	1.2	2
72	Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 640.e9-640.e17.	0.6	91

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Dabigatran Etxilate and Warfarin in "Real-World" Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2264-2273.	1.2	387
74	Alcohol intake and prognosis of atrial fibrillation. Heart, 2013, 99, 1093-1099.	1.2	51
75	Added Predictive Ability of the CHA ₂ DS ₂ -VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 335-342.	0.9	41
76	Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open, 2012, 2, e000975.	0.8	51
77	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ, The, 2012, 345, e7097-e7097.	3.0	110
78	Indirect comparison studies "are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2012, 108, 405-406.	1.8	21
79	Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 738-746.	1.2	272
80	Wireless indoor tracking network based on Kalman filters with an application to monitoring dairy cows. Computers and Electronics in Agriculture, 2010, 72, 119-126.	3.7	25
81	Visual appearance and CMT score of foremilk of individual quarters in relation to cell count of cows milked automatically. Journal of Dairy Research, 2005, 72, 49-56.	0.7	9
82	Genetic models for the inheritance of the silver colour mutation of foxes. Genetical Research, 1994, 64, 11-18.	0.3	2
83	Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study. Thrombosis and Haemostasis, 0, , .	1.8	0